In vitro study of GDNF release from biodegradable PLGA microspheres

Journal of Controlled Release

Volumn 95, Issue 3, 2004, Pages 463-475

  Aubert Pouëssel, Anne ^a   Venier Julienne, Marie Claire ^a   Clavreul, Anne ^a,b   Sergent, Michelle ^c   Jollivet, Christophe ^a   Montero Menei, Claudia N ^a   Garcion, Emmanuel ^b   Bibby, David C ^a   Menei, Philippe ^b   Benoit, Jean Pierre ^a  

^a INSERM   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

BDNF; Bovine serum albumin; Brain derived neurotrophic factor; BSA; Central nervous system; Ciliary neurotrophic factor; CNS; CNTF; EGF; ELISA; Experimental design; GDNF; Human epidermal growth factor; Microspheres; Poly(lactic co glycolic acid); Stabilization

Indexed keywords

BIOASSAY; CELLS; DISEASES; EVAPORATION; EXTRACTION; RADIOACTIVITY;

MICROSPHERES; THERAPEUTIC AGENTS;

PROTEINS;

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IODINE 125; MICROSPHERE; POLYGLACTIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; EVAPORATION; EXPERIMENTAL DESIGN; EXTRACTION; IMPLANTATION; ISOTOPE LABELING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; STEREOTAXIC SURGERY; SUSTAINED RELEASE PREPARATION;

ALZHEIMER DISEASE; ANIMALS; BIODEGRADATION, ENVIRONMENTAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IODINE RADIOISOTOPES; LACTIC ACID; MATERIALS TESTING; MICROSPHERES; NERVE GROWTH FACTORS; POLYGLYCOLIC ACID; POLYMERS; POLYPROPYLENES; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 12144285693     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2003.12.012     Document Type: Article

References (48)

1. Lin L.-F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell-line derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
2. Henderson C.E., Phillips H.S., Pollock R.A., Davies A.M., Lemeulle C., Armanini M., Simpson L.C., Moffet B., Vandlen R.A., Koliatsos V.E., Rosenthal A. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 266:1994;1062-1064.
3. Arenas E., Trupp M., Akerud P., Ibanez C.F. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron. 15:1995;1465-1473.
4. Moore M.W., Klein R.D., Fariñas I., Sauer H., Armanini M., Phillips H., Reichardt L., Ryan A.M., Carver-Moore K., Rosenthal A. Renal and neuronal abnormalities in mice lacking GDNF. Nature. 382:1996;76-79.
5. Meng X., Lindahl M., Hyvönen M.E., Parvinen M., de Rooij D.G., Hess M.W., Raatikainen-Ahokas A., Sainio K., Rauvala H., Lakso M., Pichel J.G., Westphal H., Saarma M., Sariola H. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science. 287:2000;1489-1493.
6. Lin L.-F., Zhang T.J., Collins F., Armes L.G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63:1994;758-768.
7. Albeck D.S., Hoffer B.J., Quissell D., Sanders L.A., Zerbe G., Granholm A.-C.E. A non invasive transport system for GDNF across the blood-brain barrier. NeuroReport. 8:1997;2293-2298.
8. Bensadoun J.C., Pereira de Almeida L., Fine E.G., Tseng J.L., Déglon N., Aebischer P. Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. J. Control. Release. 87:2002;107-115.
9. Lapchak P.A., Gash D.M., Collins F., Hilt D., Miller P.J., Araujo D.M. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Exp. Neurol. 145:1997;309-321.
10. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elseberry D.D., Klein M.C., Gerhardt G.A., Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain. 125:2002;2191-2201.
11. Björklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886:2000;82-98.
12. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y.P., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z.D., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
13. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., Widmer H.R., Zurn A.D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol. 149:1998;230-236.
14. Törnqvist N., Björklund L., Almqvist P., Wahlberg L., Strömberg I. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease. Exp. Neurol. 164:2000;130-138.
15. Cheng H., Hoffer B., Strömberg I., Russell D., Olson L. The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons. Exp. Brain Res. 104:1995;199-206.
16. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., Mufson E.J., Penn R., Goetz C.G., Comella C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment. Ann. Neurol. 46(3):1999;419-424.
17. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9(5):2003;589-595.
18. Benoit J.-P., Faisant N., Venier-Julienne M.-C., Menei P. Development of microspheres for neurological disorders: from basic to clinical applications. J. Control. Release. 65:2000;285-296.
19. Menei P., Daniel V., Montero-Menei C., Brouillard M., Pouplard-Barthelaix A., Benoit J.-P. Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. Biomaterials. 14(6):1993;470-478.
20. Péan J.-M., Venier-Julienne M.-C., Boury F., Menei P., Denizot B., Benoit J.-P. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J. Control. Release. 56:1998;175-187.
21. Maysinger D., Krieglstein K., Filipovic-Grcic J., Sendtner M., Unsicker K., Richardson P. Microencapsulated ciliary neurotrophic factor: physical properties and biological activities. Exp. Neurol. 138:1996;177-188.
22. Mittal S., Cohen A., Maysinger D. In vitro effects of brain derived neurotrophic factor released from microspheres. NeuroReport. 5:1994;2577-2582.
23. Aubert-Pouessel A., Bibby D.C., Venier-Julienne M.-C., Hindré F., Benoit J.-P. A novel in vitro delivery model for assessing the biological integrity of protein upon release from PLGA microspheres destinated for brain implantation. Pharm. Res. 19(7):2002;1046-1051.
24. Mathieu D., Nony J., Phan Tan Luu R. NEMROD®-W (New Efficient Methodology for Research using Optimal Design). 2000;LPRAI SARL, Marseille, France.
25. Tomac A., Widenfalk J., Lin L.-F.H., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggest a trophic role in the adult. Proc. Natl. Acad. Sci. U. S. A. 92:1995;8274-8278.
26. Ostenfeld T., Tai Y.T., Martin P., Déglon N., Aebischer P., Svendsen C.N. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J. Neurosci. Res. 69:2002;955-965.
27. Tomac A., Lindqvist E., Lin L.-F.H., Ögren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
28. Aoi M., Date I., Tomita S., Ohmoto T. The effect of intrastrital single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci. Res. 36:2000;319-325.
29. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
30. Lu X., Hagg T. Glial cell line derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. J. Comp. Neurol. 388:1997;484-494.
31. Yurek D.M. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp. Neurol. 153:1998;102-195.
32. Gerhardt G.A., Cass W.A., Huettl P., Brooks S., Zhang Z., Gash D.M. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res. 817:1999;163-171.
33. Rosenblad C., Kirik D., Björklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161:2000;503-516.
34. Gombotz W.R., Pankey S.C., Bouchard L.S., Phan D.H., MacKenzie A.P. Pearlman R., Wang Y.J. Formulation, Characterization and Stability of Protein Drugs. 1996;219-245 Plenum, New York.
35. Burke C.J., Steadman B.L., Volkin D.B., Tsai P.K., Bruner M.W., Middaugh C.R. The adsorption of proteins to pharmaceutical container surfaces. Int. J. Pharm. 86:1992;89-93.
36. Chen T. Formulation concerns of protein drugs. Drug Dev. Ind. Pharm. 18(11 and 12):1992;1311-1354.
37. Chen B.L., Arakawa T., Morris C.F., Kenney W.C., Wells C.M., Pitt C.G. Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization. Pharm. Res. 11(11):1994;1581-1587.
38. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185(2):1999;129-188.
39. Manning M.C., Patel K., Borchardt R.T. Stability of proteins pharmaceuticals. Pharm. Res. 6(11):1989;903-918.
40. Nail S.L. Formulation of proteins and peptides. Park K. Controlled Drug Delivery, Challenges and Strategies. 1997;185-203 ACS Books, Washington, DC.
41. Almon R.R., Varon S. Associations of beta nerve growth factor with bovine serum albumin as well as with the alpha and gamma subunits of the 7S macromolecule. J. Neurochem. 30:1978;1559-1567.
42. Sah H. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J. Control. Release. 58:1999;143-151.
43. Péan J.M., Boury F., Venier-Julienne M.C., Menei P., Proust J.E., Benoit J.P. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm. Res. 16(8):1999;1294-1299.
44. Boury F., Marchais H., Proust J.E., Benoit J.P. Bovine serum albumin release from poly(α-hydroxy acid) microspheres: effects of polymer molecular weight and surface properties. J. Control. Release. 45:1997;75-86.
45. Schwendeman S.P., Cardamone M., Klibanov A., Langer R., Brandon M.R. Stability of proteins and their delivery from biodegradable polymer microspheres. Cohen S., Bernstein H. Microparticulate Systems for the Delivery of Proteins and Vaccines. 1996;1-49 Marcel Dekker, New York.
46. Zhu G., Mallery S.R., Schwendeman S.P. Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: mechanism of stabilization by basic additives. Pharm. Res. 17(3):2000;351-357.
47. Jollivet C., Aubert-Pouëssel A., Clavreul A., Venier-Julienne M.-C., Remy S., Montero-Menei C., Benoit J.-P., Menei P. Reconstruction of nigro-striatal dopaminergic innervation by implantation of GDNF-releasing biodegradable microspheres. Biomaterials. 25:2004;933-942.
48. Gouhier C., Chalon S., Aubert-Pouëssel A., Venier-Julienne M.-C., Jollivet C., Benoit J.-P., Guilloteau D. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse. 44(3):2002;124-131.